New hope for tough cancers: experimental drug targets advanced tumors
Disease control
ENROLLING_BY_INVITATION
This early-stage study is testing a new drug called RNDO-564, both by itself and combined with an existing immunotherapy (pembrolizumab), in adults with advanced cancers that have stopped responding to standard treatments. The main goals are to find safe doses and see how the bod…
Phase: PHASE1 • Sponsor: Rondo Therapeutics • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC